ABVC BioPharma Postpones Distribution of BioKey Shares

What Happened

• ABVC BioPharma, Inc. (ABVC) filed an 8-K on August 4, 2026, announcing it has postponed the previously scheduled August 3, 2026 distribution of ordinary shares of BioKey (Cayman), Inc. (the “Distribution”).
• The company said the delay will allow additional time to complete administrative, regulatory and tax-related matters and that it is coordinating with The Nasdaq Stock Market LLC, The Depository Trust Company (DTC), and its transfer agent to finalize revised distribution mechanics and dates.

Key Details

• The distribution ratio remains unchanged at 0.169464 ordinary shares of BioKey for each ABVC common share.
• The previously announced record date remains unchanged (holders of record on that date will remain eligible).
• The previously announced ex-dividend date is no longer applicable and will be revised when a new distribution date is set.
• ABVC intends to announce the revised distribution date and corresponding ex-dividend date after the remaining matters are completed.

Why It Matters

• Eligible shareholders remain entitled to the same distribution ratio, but receipt of BioKey shares will be delayed until new dates are announced.
• Investors should watch for the updated ex-dividend and distribution dates (and any tax or regulatory disclosures) because timing affects when shareholders receive the shares and potential tax treatment.
• The filing signals the company is completing required administrative and regulatory steps rather than changing the economic terms of the distribution.